Abstract:Alzheimer's disease (AD) is the most common form of dementia in the elderly. However, only a few symptomatic treatments are approved for AD therapy, while no disease-modifying therapies are currently available. The amyloid cascade hypothesis posits that the deposition of amyloid β (Aβ) in the brain is the central pathological hallmark of AD. Thus, over the past 15 years, various disease-modifying immunotherapies focusing on reducing Aβ deposition have progressed from preclinical studies in AD mouse models to clinical trials in humans. Unfortunately, until now, none of the Aβ immunotherapies has produced clinically meaningful results. The main reason for this lack of efficacy is that the vaccine induces insufficiently high antibody titers, as it contains small B-cell epitope of Aβ to avoid Aβ42-specific T-cell activation. With the aim of generating a potent AD vaccine that elicits sufficiently high immunogenicity and efficiently improves cognitive capacity, we designed the protein PP-3copy-Aβ1-6-loop123, comprising three copies of Aβ1-6 inserted into three loops of a novel vaccine platform, the norovirus P particle, which could present Aβ at its surface and remarkably enhance the immunogenicity of the vaccine. We investigated the immunogenicity of PP-3copy-Aβ1-6-loop123 in three APP/PS1 transgenic mice cohorts of different ages and further determined if the vaccination using PP-3copy-Aβ1-6-loop123 had beneficial functional consequences in AD mice. Afterwards, we examined the reduction in amyloid deposition following PP-3copy-Aβ1-6-loop123 immunization in all three age cohorts and finally studied the mechanism of this novel Aβ immunotherapy. We demonstrated that PP-3copy-Aβ1-6-loop123 was able to elicit high antibody titers against Aβ42, without causing T-cell activation, in AD mice regardless of their age. Most importantly, PP-3copy-Aβ1-6-loop123 treatment successfully reduced amyloid deposition, rescued memory loss, and repaired hippocampus damage in AD mice. The Aβ antibodies induced by this active immunotherapy reacted with and disrupted aggregated Aβ, reducing its cellular toxicity. In addition, our results indicated that PP-3copy-Aβ1-6-loop123 immunization could restore Aβ homeostasis in the brain via both the “direct-targeting” and “peripheral sink” pathways. Thus, the P particle-based Aβ epitope vaccine, PP-3copy-Aβ1-6-loop123, is a sufficiently immunogenic and safe immunotherapeutic intervention for Alzheimer's disease.

Norovirus P Particle-Based Active Aβ Immunotherapy Elicits Sufficient Immunogenicity and Improves Cognitive Capacity in a Mouse Model of Alzheimer’s Disease

PRECLINICAL STUDIES OF NOROVIRUS P PARTICLE-BASED ACTIVE Aβ IMMUNOTHERAPIES FOR ALZHEIMER’S DISEASE

Active Immunization with Norovirus P Particle-Based Amyloid-Β Chimeric Protein Vaccine Induces High Titers of Anti-Aβ Antibodies in Mice

Norovirus P particle: An excellent vaccine platform for antibody production against Alzheimer’s disease

Stimulation Effects and Mechanisms of Different Adjuvants on a Norovirus P Particle-Based Active Amyloid-β Vaccine.

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

A novel Aβ epitope vaccine based on bacterium-like particle against Alzheimer's disease.

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

Co-immunization with DNA and Protein Mixture: A Safe and Efficacious Immunotherapeutic Strategy for Alzheimer's Disease in PDAPP Mice

Active Immunotherapy with 12-Mer Aβ1-42-like Assembly Vaccine Shows Efficacy in Aged 3×Tg-Ad Mice.

Norovirus P Particle-Based Tau Vaccine-Generated Phosphorylated Tau Antibodies Markedly Ameliorate Tau Pathology and Improve Behavioral Deficits in Mouse Model of Alzheimer’s Disease

Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Recombinant Dna Vaccine Against Neurite Outgrowth Inhibitors Attenuates Behavioral Deficits and Decreases Abeta in an Alzheimer'S Disease Mouse Model

A Coimmunization Vaccine of Aβ42 Ameliorates Cognitive Deficits Without Brain Inflammation in an Alzheimer’s Disease Model

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Early A Beta-Hbc Virus-Like Particles Immunization Had Better Effects on Preventing the Deficit of Learning and Memory Abilities and Reducing Cerebral A Beta Load in PDAPP Mice

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease